Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial - 01/12/15
, Oliver Riesterer, MD b, Alexandros Xyrafas d, Isabelle Opitz, MD c, Michael Beyeler, PhD e, Adrian Ochsenbein, ProfMD f, Martin Früh, MD i, Richard Cathomas, MD l, Kristiaan Nackaerts, MD m, Solange Peters, MD n, Christoph Mamot, MD o, Alfred Zippelius, ProfMD p, Carlo Mordasini, MD q, Clemens B Caspar, MD r, Katrin Eckhardt, PhD e, Ralph A Schmid, ProfMD g, Daniel M Aebersold, ProfMD h, Oliver Gautschi, MD f, Wolfgang Nagel, MD j, Michael Töpfer, MD k, Jerome Krayenbuehl, PhD b, Karin Ribi, PhD s, llja F Ciernik, MD t, Walter Weder, ProfMD cSummary |
Background |
Postoperative hemithoracic radiotherapy has been used to treat malignant pleural mesothelioma, but it has not been assessed in a randomised trial. We assessed high-dose hemithoracic radiotherapy after neoadjuvant chemotherapy and extrapleural pneumonectomy in patients with malignant pleural mesothelioma.
Methods |
We did this phase 2 trial in two parts at 14 hospitals in Switzerland, Belgium, and Germany. We enrolled patients with pathologically confirmed malignant pleural mesothelioma; resectable TNM stages T1–3 N0–2, M0; WHO performance status 0–1; age 18–70 years. In part 1, patients were given three cycles of neoadjuvant chemotherapy (cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 on day 1 given every 3 weeks) and extrapleural pneumonectomy; the primary endpoint was complete macroscopic resection (R0–1). In part 2, participants with complete macroscopic resection were randomly assigned (1:1) to receive high-dose radiotherapy or not. The target volume for radiotherapy encompassed the entire hemithorax, the thoracotomy channel, and mediastinal nodal stations if affected by the disease or violated surgically. A boost was given to areas at high risk for locoregional relapse. The allocation was stratified by centre, histology (sarcomatoid vs epithelioid or mixed), mediastinal lymph node involvement (N0–1 vs N2), and T stage (T1–2 vs T3). The primary endpoint of part 1 was the proportion of patients achieving complete macroscopic resection (R0 and R1). The primary endpoint in part 2 was locoregional relapse-free survival, analysed by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00334594.
Findings |
We enrolled patients between Dec 7, 2005, and Oct 17, 2012. Overall, we analysed 151 patients receiving neoadjuvant chemotherapy, of whom 113 (75%) had extrapleural pneumonectomy. Median follow-up was 54·2 months (IQR 32–66). 52 (34%) of 151 patients achieved an objective response. The most common grade 3 or 4 toxic effects were neutropenia (21 [14%] of 151 patients), anaemia (11 [7%]), and nausea or vomiting (eight [5%]). 113 patients had extrapleural pneumonectomy, with complete macroscopic resection achieved in 96 (64%) of 151 patients. We enrolled 54 patients in part 2; 27 in each group. The main reasons for exclusion were patient refusal (n=20) and ineligibility (n=10). 25 of 27 patients completed radiotherapy. Median total radiotherapy dose was 55·9 Gy (IQR 46·8–56·0). Median locoregional relapse-free survival from surgery, was 7·6 months (95% CI 4·5–10·7) in the no radiotherapy group and 9·4 months (6·5–11·9) in the radiotherapy group. The most common grade 3 or higher toxic effects related to radiotherapy were nausea or vomiting (three [11%] of 27 patients), oesophagitis (two [7%]), and pneumonitis (two [7%]). One patient died of pneumonitis. We recorded no toxic effects data for the control group.
Interpretation |
Our findings do not support the routine use of hemithoracic radiotherapy for malignant pleural mesothelioma after neoadjuvant chemotherapy and extrapleural pneumonectomy.
Funding |
Swiss Group for Clinical Cancer Research, Swiss State Secretariat for Education, Research and Innovation, Eli Lilly.
Le texte complet de cet article est disponible en PDF.Plan
Vol 16 - N° 16
P. 1651-1658 - décembre 2015 Retour au numéro
Article précédent
- Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
- Didier Meulendijks, Linda M Henricks, Gabe S Sonke, Maarten J Deenen, Tanja K Froehlich, Ursula Amstutz, Carlo R Largiadèr, Barbara A Jennings, Anthony M Marinaki, Jeremy D Sanderson, Zdenek Kleibl, Petra Kleiblova, Matthias Schwab, Ulrich M Zanger, Claire Palles, Ian Tomlinson, Eva Gross, André B P van Kuilenburg, Cornelis J A Punt, Miriam Koopman, Jos H Beijnen, Annemieke Cats, Jan H M Schellens
- Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study
- Takaya Moriyama, Monika L Metzger, Gang Wu, Rina Nishii, Maoxiang Qian, Meenakshi Devidas, Wenjian Yang, Cheng Cheng, Xueyuan Cao, Emily Quinn, Susana Raimondi, Julie M Gastier-Foster, Elizabeth Raetz, Eric Larsen, Paul L Martin, W Paul Bowman, Naomi Winick, Yoshihiro Komada, Shuoguo Wang, Michael Edmonson, Heng Xu, Elaine Mardis, Robert Fulton, Ching-Hon Pui, Charles Mullighan, William E Evans, Jinghui Zhang, Stephen P Hunger, Mary V Relling, Kim E Nichols, Mignon L Loh, Jun J Yang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?